Stockreport

Intellia Therapeutics lands genome editing technology patent in Europe [Seeking Alpha]

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview
PDF Intellia Therapeutics (NASDAQ: NTLA ) announces that the European Patent Office granted a patent broadly covering the CRISPR/Cas9 genome editing technology. Th [Read more]